OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The principal aim of the study is to determine the effects n3-PUFA on top of standard therapy
on surrogate markers of disease severity and/or prognosis in patients with PAD.
Treatment duration will be 3 months, final follow-up is planned at 6 months after inclusion.
Primary outcome parameter is endothelial function assessed by flow-mediated vasodilation
using brachial artery ultrasound.
Secondary outcome measures comprise maximum and pain-free treadmill walking distance, pulse
wave velocity, whole blood viscosity, platelet activation and plasma markers of inflammation.